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Already in his famous side-chain theory (1900), P Ehrlich formulated the
hypothesis that immune cells could express receptors susceptible to react
against normal components of the body. In that case, however very improb-
able for him, he claimed that the organism should deploy specific mech-
anisms to escape from this difficulty (horror autotoxicus). In the second
edition of ‘The Production of Antibodies’ (1949), F Macfarlane Burnet
and F Fenner proposed the principle of self/nonself discrimination as the
cardinal point of immune physiology, as well as the concept of self-markers
for antigens encountered by precursors of immunocytes during embryonic
life, to which thenceforth immunological tolerance could never be broken
later in life. Autoimmunity, if this should occur, would then depend on
‘forbidden’ immune clones that later arose through somatic mutation. Since
that time, self-tolerance has become a cornerstone of immune physiology,
together with diversity, specificity and memory of the immune response.
The absence or breakdown of self-tolerance is responsible for the progress-
ive development of autoimmune diseases, either systemic (such as lupus
erythematosus) or organ-specific (such as autoimmune endocrine diseases).
All endocrine glands without exception may become deficient because of an
autoimmune response directed against one or a few endocrine tissue-specific
autoantigens. A legitimate question then is to understand why autoimmune
pathogenic processes so frequently aggress endocrine tissues. The discovery
of the intrathymicmechanisms responsible for the installation of central self-
tolerance has provided a number of answers to this important question.
Among these answers, an important one concerns the true nature of self that
is presented in the thymus to differentiating T cells during fetal life. Since
its formulation some 60 years ago, self had been a seminal word coined in
immunology’s language first as a fecund metaphor with some equivocal
correlations to philosophy, psychology, and neurocognitive sciences. For
unknown reasons, there were no serious attempts to elucidate the bio-
chemical identity of self before a number of essential consecutive studies in
the late 1980s and in the 1990s.
In all living species, (neuro)endocrine and innate immune systems have
coevolved until now without any apparent problem. Some 470millions years
ago, while the rudiments of an anticipatory immune response already existed
in early jawless vertebrates (agnathes), recombinase-dependent adaptive
immunity appeared for the first time in jawed fishes (gnathostomes). As
demonstrated by S Tonegawa and M Davis, gene recombination in somatic
lymphoid cells is responsible for the random generation of diverse immune
receptors for antigens, B-cell (5  1013 BCR combinations) and T-cell
receptors (1018 TCR combinations). Because of its inherent risk of auto-
toxicity, the emergence of this sophisticated type of immune response
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cal self-tolerance. The progressive rise in the level of
immune diversity and complexity may explain why fail-
ures in self-tolerance (autoimmune diseases) are increas-
ingly detected during evolution, with the maximum
observed in the human species. Of note, the first thymus
also appeared with cartilaginous fishes and, a posteriori, it
can be legitimately stated that the emergence of this
organ was required for a further ‘pacific’ coevolution of
the immune and neuroendocrine systems. Two essential
and closely associated mechanisms are responsible for the
thymus-dependent central arm of self-tolerance: clonal
deletion of self-reactive T cells stochastically generated
by the recombinase-dependent generation of TCR diver-
sity, and differentiation of self-specific natural regulatory
T cells (Treg), which are able to inhibit in periphery self-
reactive T cells having escaped thymic negative selec-
tion. As recalled several times by NA Mitchison, B-cell
tolerance is primarily due to a lack of T-cell help and,
therefore, the thymus and T lymphocytes play a predo-
minant role in the establishment of immunological tol-
erance and development of autoimmunity. In addition,
more and more experimental data are providing firm
evidence that a disruption in the tolerogenic pathways
operating during intrathymic T-cell differentiation con-
stitutes a major event in the initiation of autoimmune
diseases.
Immunoneuroendocrinology was recognized as a scien-
tific field early in the 20th century, soon after immunology
was identified as a specific domain of investigation. By the
1930s, H Selye introduced the concept of stress-induced,
adrenal cortex-mediated thymus involution and second-
ary immunosuppression. In the 1940s, the discovery and
chemical synthesis of glucocorticoids and their thera-
peutic usage in rheumatoid arthritis represented a major
progress recognized by the 1950 Nobel Prize in medicine
and physiology. Before the seminal work conducted in
the 1960s by JFAP Miller, who established the thymus as
the lymphoid organ ensuring T-cell generation (thymo-
poiesis), this organ was assumed to be a specific gland
belonging to the endocrine system. However, as we have
shown, the model of (neuro)endocrine cell-to-cell sig-
naling failed to accurately describe the interactions be-
tween the thymic stromal network and developing T
cells. Actually, the processing of neuroendocrine-related
precursors synthesized in thymic epithelial cells is not
coupled to classical (neuro)secretion, but to constitutive
pathways involved in membrane targeting and self-pres-
entation by the thymic proteins of the major histocom-
patibility complex. The dissection of the intricate cellular
and molecular interactions between the major systems of
cell-to-cell signaling — the neural, endocrine, and
immune systems — was initiated in the 1980s and this
scientific domain has received only gradual acceptance by
the scientific community. Endocrinologists did not hes-
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fundamental relevance to physiology. Recently, immu-
noendocrinology has been expanded exponentially, and
the immunological self-tolerance of neuroendocrine
proteins was proved to be an obvious necessity for pre-
serving general homeostasis. As it will be largely illus-
trated in this issue, many hormones and neuropeptides
exert an important control upon the immune and inflam-
matory responses through binding to and activation of
neuroendocrine receptors expressed by immunocompe-
tent cells. If self-tolerance to neuroendocrine ligands and
receptors were not firmly installed, then the risk of
developing autoimmune phenomena would have been
extremely high and species survival would have been
severely compromised. The primary objective of this
issue is to show the pharmacological importance of immu-
noendocrinology for modulation of thymus functions and
regeneration of immune defenses, as well as for the
therapeutic approach of type 1 diabetes and other auto-
immune endocrine diseases.
From a clinical point of view, aging of the immune
system (immunosenescence) is characterized by a
higher susceptibility to various infections, an increase
in the incidence of cancer and autoimmune diseases, as
well as a decrease in response to vaccinations. Since a
long time, thymic adipose ‘involution’ is considered as
the prominent feature of immunosenescence. It is
associated with a marked decrease in the generation
of diverse T cells (in particular naı¨ve CD4+ T cells), an
expansion of memory CD8+ T cells, and a diminished
influence of thymus-dependent central self-tolerance.
The involution of the thymus following hypophysect-
omy was the first evidence for the control of the immune
system by a major endocrine gland (Smith, 1930). In
1932, the Swedish thymologist JA Hammar observed a
positive relationship between the size of the hypophysis
and the development of thymic medullary epithelium in
young rabbits. The GH receptor belongs to the
extended family of receptors to type I cytokines and
pioneering studies by KW Kelley and colleagues unam-
biguously demonstrated that GH administration
reverses age-dependent thymic atrophy. Today, thymus
function can be clinically monitored through the soph-
isticated technology of signal-joint (sj) and b TCR
excision circles (TRECs) that are generated during
the intrathymic recombination of gene segments encod-
ing the variable parts of the TCR a and b chains. Using
this methodology, it is now possible to measure with
precision the impact exerted in vivo by the endocrine
system upon two important parameters of thymus physi-
ology, the intrathymic proliferation of T-cell precursors
(sj/b TREC ratio) and the thymic output of naı¨ve T
cells (sjTRECs). Several chapters of this issue will
further illustrate the importance of the somatotrope
ghrelin/growth hormone (GH)/insulin-like growth factor
1 (IGF-1) in the regulation of thymus biology. Thee immune and neuroendocrine systems: pharmacological implications, Curr Opin Pharmacol
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in the elderly, in AIDS, and in a series of hemato-
oncological diseases. From these in-depth studies, it
is highly probable that GH, GH secretagogues (such
as ghrelin), GH and ghrelin receptor agonists, or IGF-1Please cite this article in press as: Geenen V, The thymus as an obligatory intersection between th
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